These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

295 related items for PubMed ID: 9263356

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Aspirin in essential thrombocythemia: status quo and quo vadis.
    Griesshammer M, Bangerter M, van Vliet HH, Michiels JJ.
    Semin Thromb Hemost; 1997; 23(4):371-7. PubMed ID: 9263354
    [Abstract] [Full Text] [Related]

  • 3. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera.
    Michiels JJ, Berneman Z, Schroyens W, Finazzi G, Budde U, van Vliet HH.
    Semin Thromb Hemost; 2006 Sep; 32(6):589-604. PubMed ID: 16977569
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia.
    Elliott MA, Tefferi A.
    Br J Haematol; 2005 Feb; 128(3):275-90. PubMed ID: 15667529
    [Abstract] [Full Text] [Related]

  • 6. Thrombosis and bleeding in polycythemia vera and essential thrombocythemia: pathogenetic mechanisms and prevention.
    Landolfi R, Cipriani MC, Novarese L.
    Best Pract Res Clin Haematol; 2006 Feb; 19(3):617-33. PubMed ID: 16781491
    [Abstract] [Full Text] [Related]

  • 7. [What vascular events suggest a myeloproliferative disorder?].
    Hachulla E, Rose C, Trillot N, Caulier-Leleu MT, Pasturel-Michon U.
    J Mal Vasc; 2000 Dec; 25(5):382-387. PubMed ID: 11148402
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Platelet-mediated microvascular inflammation and thrombosis in thrombocythemia vera: a distinct aspirin-responsive arterial thrombophilia, which transforms into a bleeding diathesis at increasing platelet counts.
    Michiels JJ.
    Pathol Biol (Paris); 2003 Apr; 51(3):167-75. PubMed ID: 12781799
    [Abstract] [Full Text] [Related]

  • 10. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
    Michiels JJ, Berneman Z, Van Bockstaele D, van der Planken M, De Raeve H, Schroyens W.
    Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Pathogenesis and management of bleeding in essential thrombocythemia and polycythemia vera.
    Elliott MA, Tefferi A.
    Curr Hematol Rep; 2004 Sep; 3(5):344-51. PubMed ID: 15341701
    [Abstract] [Full Text] [Related]

  • 13. Acquired abnormalities of von Willebrand factor: facts to consider in patients with unexpected bleeding.
    Ruggeri ZM.
    J Lab Clin Med; 1993 Mar; 121(3):377-9. PubMed ID: 8445284
    [No Abstract] [Full Text] [Related]

  • 14. Relation of platelet abnormalities to thrombosis and hemorrhage in chronic myeloproliferative disorders.
    Wehmeier A, Südhoff T, Meierkord F.
    Semin Thromb Hemost; 1997 Mar; 23(4):391-402. PubMed ID: 9263357
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Aspirin-responsive, migraine-like transient cerebral and ocular ischemic attacks and erythromelalgia in JAK2-positive essential thrombocythemia and polycythemia vera.
    Michiels JJ, Berneman Z, Gadisseur A, Lam KH, De Raeve H, Schroyens W.
    Acta Haematol; 2015 Mar; 133(1):56-63. PubMed ID: 25116182
    [Abstract] [Full Text] [Related]

  • 19. [Successful management of intraperitoneal bleeding with platelet apheresis and von Willebrand factor supplementation in a patient with essential thrombocythemia and acquired von Willebrand syndrome].
    Ueki T, Takeshige K, Sumi M, Ueno M, Ichikawa N, Kobayashi H.
    Rinsho Ketsueki; 2017 Mar; 58(8):922-926. PubMed ID: 28883275
    [Abstract] [Full Text] [Related]

  • 20. Platelet-mediated thrombotic complications in patients with ET: Reversal by aspirin, platelet reduction, and not by coumadin.
    Michiels JJ, Berneman Z, Schroyens W, Koudstaal PJ, Lindemans J, van Vliet HH.
    Blood Cells Mol Dis; 2006 Mar; 36(2):199-205. PubMed ID: 16510297
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.